Product Information
PROPRANOLOL ER 160 MG CAPSULE is a generic product labeled by Actavis Pharma, Inc., priced at $0.3050 per EA under NDC 00228278111. Its NADAC has been published 671 times since Nov 28, 2013.
FDA first approved this application on Aug 10, 2007. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
160 mg/1
Manufacturer
Actavis Pharma, Inc.NDC
00228278111
Classification
Generic
Dosage Form
CAPSULE, EXTENDED RELEASE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
PROPRANOLOL HYDROCHLORIDEApproval Type
Generic (ANDA)
FDA Application
ANDA078494FDA Approved
8/10/2007
TE Code
AB
On Market Since
8/10/2007
Pharmacological Classes
Price Statistics
The NADAC for PROPRANOLOL ER 160 MG CAPSULE has been published 671 times since Nov 28, 2013, and over the history we have for it it has declined 73.6%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.3050 per EA |
|---|---|
| All-time high | $2.9306 (Nov 12, 2014) |
| All-time low | $0.2252 (Apr 17, 2024) |
| 52-week high | $0.3399 |
| 52-week low | $0.3050 |
| Median price | $1.0091 |
| Average price | $1.2584 |
| Largest weekly change | +69.0% (Jan 22, 2014) |
| Weeks tracked | 671 |
| Tracking since | Nov 28, 2013 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the Propranolol Hydrochloride market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Actavis Pharma, Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Propranolol Hydrochloride market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
beta-Adrenergic Blocker class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of PROPRANOLOL ER 160 MG CAPSULE?
The current National Average Drug Acquisition Cost (NADAC) for PROPRANOLOL ER 160 MG CAPSULE, manufactured by Actavis Pharma, Inc., is $0.3050 per EA (NDC 00228278111), effective Sep 30, 2026.
How has the price of PROPRANOLOL ER 160 MG CAPSULE changed over time?
Over the history we have for it, the NADAC for PROPRANOLOL ER 160 MG CAPSULE has declined 73.6%. It has been tracked across 671 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for PROPRANOLOL ER 160 MG CAPSULE?
Since Nov 28, 2013, the NADAC for PROPRANOLOL ER 160 MG CAPSULE has ranged from a low of $0.2252 (Apr 17, 2024) to a high of $2.9306 (Nov 12, 2014), with a median of $1.0091 per EA.
Are there cheaper alternatives to PROPRANOLOL ER 160 MG CAPSULE?
No other NADAC-published product currently shares the active ingredient and strength of PROPRANOLOL ER 160 MG CAPSULE in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures PROPRANOLOL ER 160 MG CAPSULE?
PROPRANOLOL ER 160 MG CAPSULE (NDC 00228278111) is labeled by Actavis Pharma, Inc., and CMS classifies it as a generic product.